TRANSDERMAL COMPOSITION CONTAINING THERAPEUTIC AGENT FOR PARKINSON'S DISEASE

摘要

Disclosed is a transdermal pharmaceutical which uses non-ergot antidopaminergic D2 receptor agonists such as ropinirole hydrochlorides or pramipexole hydrochlorides. The disclosed pharmaceutical takes into account skin safety and drug stability, exhibits excellent skin permeability, and uses the non-ergot antidopaminergic D2 receptor agonists such as ropinirole that are currently used as oral preparations in a new manner as transdermal agents. The disclosed transdermal pharmaceutical is formed by combining a non-ergot antidopaminergic D2 receptor agonist with a hydrophobic solvent and surfactant to form a minute micelle in a water-polyhydric alcohol solvent, and then preparing a colloidal solution containing the non-ergot antidopaminergic D2 receptor agonist. By selecting and adjusting the pH of the colloidal solution, the non-ergot antidopaminergic D2 receptor agonists project from the exterior of the micelle, increasing the transdermal absorbability and the initial permeability of the non-ergot antidopaminergic D2 receptor agonists.